Literature DB >> 33338426

Immunomodulation by targeted anticancer agents.

Giulia Petroni1, Aitziber Buqué1, Laurence Zitvogel2, Guido Kroemer3, Lorenzo Galluzzi4.   

Abstract

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRAF; CD8(+) cytotoxic T lymphocytes; CDK4/CDK6; CGAS signaling; DNA damage response; EGFR; KRAS; T(REG) cells; TGF-β; immune checkpoint blockers; immunogenic cell death

Year:  2020        PMID： 33338426     DOI： 10.1016/j.ccell.2020.11.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  35 in total

Review 1.  Immunogenic cell stress and death.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Claudia Galassi; Laurence Zitvogel
Journal:  Nat Immunol       Date:  2022-02-10       Impact factor: 25.606

Review 2.  Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.

Authors:  Giulia Petroni; Aitziber Buqué; Lisa M Coussens; Lorenzo Galluzzi
Journal:  Nat Rev Drug Discov       Date:  2022-03-15       Impact factor: 84.694

Review 3.  Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.

Authors:  Giampaolo Bianchini; Carmine De Angelis; Luca Licata; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2021-11-09       Impact factor: 66.675

Review 4.  Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.

Authors:  Giulia Petroni; Lewis C Cantley; Laura Santambrogio; Silvia C Formenti; Lorenzo Galluzzi
Journal:  Nat Rev Clin Oncol       Date:  2021-11-24       Impact factor: 66.675

Review 5.  Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights.

Authors:  Jiao-Jiao Ni; Zi-Zhen Zhang; Ming-Jie Ge; Jing-Yu Chen; Wei Zhuo
Journal:  Acta Pharmacol Sin       Date:  2022-08-04       Impact factor: 7.169

Review 6.  Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.

Authors:  Javid Moslehi; Andrew H Lichtman; Arlene H Sharpe; Lorenzo Galluzzi; Richard N Kitsis
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

7.  Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma.

Authors:  Yuyin Fu; Yujia Peng; Shengyan Zhao; Jun Mou; Lishi Zeng; Xiaohua Jiang; Chengli Yang; Cheng Huang; Yuyan Li; Yin Lu; Mengdan Wu; Yanfang Yang; Ting Kong; Qinhuai Lai; Yangping Wu; Yuqin Yao; Yuxi Wang; Lantu Gou; Jinliang Yang
Journal:  Front Cell Dev Biol       Date:  2021-07-08

8.  Inflammatory Cell Death, PANoptosis, Mediated by Cytokines in Diverse Cancer Lineages Inhibits Tumor Growth.

Authors:  R K Subbarao Malireddi; Rajendra Karki; Balamurugan Sundaram; Balabhaskararao Kancharana; SangJoon Lee; Parimal Samir; Thirumala-Devi Kanneganti
Journal:  Immunohorizons       Date:  2021-07-21

9.  Immunology of Cell Death in Cancer Immunotherapy.

Authors:  Lorenzo Galluzzi; Abhishek D Garg
Journal:  Cells       Date:  2021-05-15       Impact factor: 6.600

10.  Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects.

Authors:  Adriana Petrazzuolo; Maria Perez-Lanzon; Isabelle Martins; Peng Liu; Oliver Kepp; Véronique Minard-Colin; Maria Chiara Maiuri; Guido Kroemer
Journal:  Cell Death Dis       Date:  2021-07-16       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.